Compare Davita Inc (DVA) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Davita Inc trades at $180.7 (market cap $11.53B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.44B). The key difference: Davita Inc is far larger — about 3.4× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.07% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| DVA | ZGN | |
|---|---|---|
Market Cap | $11.53B | $3.44B |
Volume | 444,368 | 781,107 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $15.25 |
52-Week Low | $103.87 | $8.69 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $4.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), revenue growth from $11.6B to $13.6B (2022-2025), and attractive valuation at P/E 15.43. Recent partnership expansion with Humana for value-based kidney care and institutional buying by BlackRock ($547.5M) support positive momentum. Operating cash flow remains robust at $1.89B (2025), though net cash flow turned negative due to debt repayments.
Outlook: DVA offers upside to consensus target ($235.67) with 29% potential, backed by earnings growth and strategic partnerships. Risks include high debt (debt-to-asset 65.55%), regulatory pressures, and margin volatility. Analyst consensus leans Hold (52.17%) amid balanced growth prospects and financial leverage concerns.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
